Advanced Cell Technology

ACT begins trials for macular dystrophy treatment

Friday, July 15, 2011

Advanced Cell Technology announced the dosing of the first patients in each of its two phase I/II clinical trials for Stargardt’s macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were treated by Steven Schwartz, M.D., at the David Geffen School of Medicine at UCLA. Robert Lanza, M.D., chief scientific officer of ACT, attended the procedures. Both patients successfully underwent the outpatient transplantation surgeries and are recovering uneventfully.

[Read More]

ACT and Oregon Health & Science University collaborate in SMD trials

Monday, May 16, 2011

Advanced Cell Technology (ACT), a company involved in regenerative medicine, reports that the Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU) has received institutional review board (IRB) approval to be a site for its phase I/II human clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

[Read More]

Advanced Cell Technology receives IRB approval for SMD/AMD studies at UCLA

Friday, April 29, 2011

Massachusetts-based Advanced Cell Technology, a biotechnology company focused on developing regenerative medicine, reports that the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA) has received institutional review board (IRB) approval to be a site for its phase I/II human clinical trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

[Read More]